Roflumilast therapy in COPD − Update and Trials

  • Om Prakash Giri Department of Pulmonary Medicine, Darbhanga Medical College and Hospital, Darbhanga
  • Vishal Prakash Giri Department of Pharmacology, Teerthanker Mahaveer Medical College & Research Centre, Moradabad
Keywords: Anti-inflammatory; Chronic obstructive pulmonary disease; Phosphodiesterase 4 inhibitor; Roflumilast


Chronic Obstructive Pulmonary Disease (COPD) represents an important public health challenge that is both preventable and treatable. Pharmacological treatment regimen for COPD needs to be patient specific. Hence  management of  COPD    should  be  based  on  strategy  considering  both  disease  impact  and  future  risk  of  disease  progression ( especially of  exacerbation ). Risk of exacerbations significantly increases in GOLD 3 and GOLD 4 COPD. Exacerbations  increase  the   decline in  lung function , deteorriation  in  health  status  and  risk   of  death.

Roflumilast   is   a   phosphodiesterase-4 (PDE4) inhibitor. It reduces   risk of moderate to severe   exacerbations in patients   of   GOLD 3   & GOLD 4   COPD. It  has  no  direct  bronchodilator  activity, although it  has  been  shown  to  improve  FEV1  in  patients treated  with   inhaled  long-acting  bronchodilator. Adverse  effects  may occur  early during the  treatment  but  these  are  reversible  and  diminish  overtime  with  continued  treatment .


Download data is not yet available.


1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. [Online], 2015.
2. Roflumilast product information. European Medicines Agency [Internet]. 2014 [cited 2014 Nov 29]. Available from:
3. Hanania NA, Calverley PM, Dransfield MT, et al. Pooled subpopulation analyses of the effect of Roflumilast on exacerbation and lung function in COPD. Respir Med. 2014; 108(2): 366-75.
4. Rennard SI, Sun SX, Tourkodimitris S, et al. Roflumilast and dyspnea in patient with moderate to very severe COPD: A pooled analysis of four clinical trials. Int J Chron Obstruct Pulmon Dis. 2014; 9: 657-73.
5. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease .Conchrane Database Syst Rev. 2013 Nov 4; 11: CD002309.
6. Sinopal’nikov AI. Novel trends in pharmacotherapy of COPD- prevention of exacerbation (focus on Roflumilast).
[Article in Russian]. Klin Med (Mosk). 2014; 92(2): 57-64.
7. Lipari M, Benipal H, Kale-Pardhan P. Roflumilast in the management of COPD. Am J Health Syst Pharm. 2013; 70 (23): 2087-95.
8. Yan JH, Gu WJ, Pan L. Efficacy and safety of Roflumilast in patients with stable chronic obstructive pulmonary disease : A meta-analysis. Pulm Pharmacol Ther. 2014; 27(1): 83-9.
9. Zheng J, Yang J, Zhou X, et al. Roflumilast for the treatment of COPD in an Asian population: A randomized, double-blind, parallel-group study. Chest 2014; 145(1): 44-52.
How to Cite
Giri OP, Giri VP. Roflumilast therapy in COPD − Update and Trials. Int Arch BioMed Clin Res [Internet]. 2015Sep.3 [cited 2019Dec.5];1(1):31-6. Available from: